AI in the development of vaccines for emerging and re-emerging diseases
DOI:
https://doi.org/10.56294/saludcyt2024.1285Keywords:
Artificial intelligence, Vaccine development, Emerging diseases, Immunology, Genomic data ethicsAbstract
Introduction: The integration of artificial intelligence (AI) into vaccine development has revolutionized traditional methodologies, significantly enhancing the speed, precision, and scalability of immunological research. Emerging and re-emerging infectious diseases, driven by zoonotic spillovers, antimicrobial resistance, and global environmental changes, pose substantial challenges. Addressing these requires innovative approaches, with AI playing a pivotal role in advancing immunological solutions.
Development: AI applications in vaccinology include antigen detection, adjuvant optimization, and immune response simulation. Deep learning algorithms streamline the identification of immunogenic targets and conserved antigens, enabling vaccine development for highly mutable pathogens such as SARS-CoV-2, HIV, and influenza. Case studies demonstrate AI's transformative impact, including its role in the rapid creation of mRNA vaccines for COVID-19, identification of promising antigens for malaria, and enhanced efficacy of influenza vaccines through predictive modeling. However, challenges such as unequal access to technology, biases in data models, and ethical concerns regarding genomic data privacy persist. Recommendations to address these barriers include increasing data diversity, strengthening ethical frameworks, and investing in global infrastructure to democratize AI-driven innovations.
Conclusions: AI's ability to reduce time and cost, improve vaccine precision, and enable personalized immunization strategies positions it as a cornerstone of modern vaccinology. With continued advancements and equitable implementation, AI holds the potential to reshape vaccine development, improve pandemic preparedness, and address longstanding public health disparities globally.
References
1. Chernak ED, Influenza A, Coronavirus N. Evolving and emerging threats. Public Health Emergencies: Case Studies, Competencies, and Essential Services of Public Health. 2021;226. DOI: https://doi.org/10.1891/9780826149039.0019
2. Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182(5):1077–92. DOI: https://doi.org/10.1016/j.cell.2020.08.021
3. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines (Basel). 2021;9(12):1490. DOI: https://doi.org/10.3390/vaccines9121490
4. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589–603. DOI: https://doi.org/10.1016/j.cell.2021.02.030
5. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021;25:1315–60. DOI: https://doi.org/10.1007/s11030-021-10217-3
6. Katwaroo AR, Adesh VS, Lowtan A, Umakanthan S. The diagnostic, therapeutic, and ethical impact of artificial intelligence in modern medicine. Postgrad Med J. 2024;100(1183):289–96. DOI: https://doi.org/10.1093/postmj/qgad135
7. Farahani AF, Kasraei N. Evaluating the Impact of Artificial Intelligence on Vaccine Development: Lessons Learned from the COVID-19 Pandemic. medRxiv. 2024;2010–24. DOI: https://doi.org/10.1101/2024.10.23.24315991
8. Kannan S, Subbaram K, Faiyazuddin M. Artificial intelligence in vaccine development: Significance and challenges ahead. In: A Handbook of Artificial Intelligence in Drug Delivery. Elsevier; 2023. p. 467–86. DOI: https://doi.org/10.1016/B978-0-323-89925-3.00017-4
9. Thalange A V, Patil AR, Athavale VA. A Review of Artificial Intelligence and Machine Learning for Vaccine Research. In: The International Conference on Recent Innovations in Computing. Springer; 2023. p. 85–101. DOI: https://doi.org/10.1007/978-981-97-2839-8_7
10. Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, et al. Leveraging artificial intelligence in vaccine development: A narrative review. J Microbiol Methods. 2024;106998. DOI: https://doi.org/10.1016/j.mimet.2024.106998
11. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. DOI: https://doi.org/10.1038/s41591-018-0300-7
12. Lawrence P, Heung M, Nave J, Henkel C, Escudero-Pérez B. The natural virome and pandemic potential: Disease X. Curr Opin Virol. 2023;63:101377. DOI: https://doi.org/10.1016/j.coviro.2023.101377
13. Paul J. Introduction to Infectious Diseases. In: Disease Causing Microbes. Springer; 2024. p. 1–63. DOI: https://doi.org/10.1007/978-3-031-28567-7_1
14. Sánchez CA, Venkatachalam‐Vaz J, Drake JM. Spillover of zoonotic pathogens: A review of reviews. Zoonoses Public Health. 2021;68(6):563–77. DOI: https://doi.org/10.1111/zph.12846
15. Rodriguez-Morales AJ, Paniz-Mondolfi AE, Faccini-Martínez ÁA, Henao-Martínez AF, Ruiz-Saenz J, Martinez-Gutierrez M, et al. The constant threat of zoonotic and vector-borne emerging tropical diseases: living on the edge. Vol. 2, Frontiers in tropical diseases. Frontiers Media SA; 2021. p. 676905. DOI: https://doi.org/10.3389/fitd.2021.676905
16. Spencer JNH, Marasco D, Eichinger M. Planning for Emerging Infectious Disease Pandemics: Definitions, the role of planners, and learning from the avian influenza outbreak of 2004–2005. Journal of the American planning association. 2022;88(1):113–26. DOI: https://doi.org/10.1080/01944363.2021.1930107
17. Bhanye AS, Bhanye JI. Urban health in the 21st century: Exploring innovative measures to reduce the spread of communicable diseases. Developments in Environmental Science. 2024;15:503–27. DOI: https://doi.org/10.1016/B978-0-443-21948-1.00024-8
18. Wainaina M, Wasonga J, Cook EAJ. Epidemiology of human and animal leptospirosis in Kenya: A systematic review and meta-analysis of disease occurrence, serogroup diversity and risk factors. PLoS Negl Trop Dis. 2024;18(9):e0012527. DOI: https://doi.org/10.1371/journal.pntd.0012527
19. Kaslow RA, Bell DM. Epidemiology and Control: From Principles to Pandemics. In: Viral Infections of Humans: Epidemiology and Control. Springer; 2022. p. 1–80. DOI: https://doi.org/10.1007/978-1-4939-9544-8_1-1
20. Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol. 2022;106:25–56. DOI: https://doi.org/10.1007/s00253-021-11713-0
21. Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med. 2021;27(3):401–10. DOI: https://doi.org/10.1038/s41591-021-01282-0
22. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. New England journal of medicine. 2020;382(21):1969–73. DOI: https://doi.org/10.1056/NEJMp2005630
23. Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children: Where we stand now. Cureus. 2023;15(2). DOI: https://doi.org/10.7759/cureus.35154
24. Emane AKA, Guo X, Takiff HE, Liu S. Highly transmitted M. tuberculosis strains are more likely to evolve MDR/XDR and cause outbreaks, but what makes them highly transmitted? Tuberculosis. 2021;129:102092. DOI: https://doi.org/10.1016/j.tube.2021.102092
25. Sun-Waterhouse DX, Chen XY, Liu ZH, Waterhouse GI, Kang WY. Transformation from traditional medicine-food homology to modern food-medicine homology. Food & Medicine Homology. 2024;1(1):9420014. DOI: https://doi.org/10.26599/FMH.2024.9420014
26. Redford KH, Adams WM. Strange natures: Conservation in the era of synthetic biology. Yale University Press; 2021. DOI: https://doi.org/10.12987/9780300258677
27. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules. 2020;26(1):39. DOI: https://doi.org/10.3390/molecules26010039
28. Vecchio R, Gentile L, Tafuri S, Costantino C, Odone A. Exploring future perspectives and pipeline progression in vaccine research and development. Ann Ig. 2024;36(4):446–61.
29. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354. DOI: https://doi.org/10.3389/fimmu.2020.585354
30. Zhuang L, Ye Z, Li L, Yang L, Gong W. Next-generation TB vaccines: progress, challenges, and prospects. Vaccines (Basel). 2023;11(8):1304. DOI: https://doi.org/10.3390/vaccines11081304
31. Patel MN, Patel AJ, Nandpal MN, Raval MA, Patel RJ, Patel AA, et al. Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape. Naunyn Schmiedebergs Arch Pharmacol. 2024;1–24. DOI: https://doi.org/10.1007/s00210-024-03466-0
32. Hosseinian SA, Hajati MH. A comprehensive review of the zoonotic potential of avian influenza viruses: a globally circulating threat to pandemic influenza in human. Journal of Zoonotic Diseases. 2024;
33. Gangopadhayya A, Bhukya PL. Factors Contributing to the Emergence of Viral Diseases. In: Emerging Human Viral Diseases, Volume I: Respiratory and Haemorrhagic Fever. Springer; 2023. p. 3–69. DOI: https://doi.org/10.1007/978-981-99-2820-0_1
34. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595(7865):17–8. DOI: https://doi.org/10.1038/d41586-021-01696-3
35. Rubinstein M, Makhon A, Losev Y, Valenci GZ, Gatt YE, Margalit H, et al. Prolonged survival of a patient with active MDR-TB HIV co-morbidity: insights from a Mycobacterium tuberculosis strain with a unique genomic deletion. Front Med (Lausanne). 2023;10:1292665. DOI: https://doi.org/10.3389/fmed.2023.1292665
36. Abhinand CS, Prabhakaran AA, Krishnamurthy A, Raju R, Keshava Prasad TS, Nair AS, et al. SARS-CoV-2 variants infectivity prediction and therapeutic peptide design using computational approaches. J Biomol Struct Dyn. 2023;41(20):11166–77. DOI: https://doi.org/10.1080/07391102.2022.2160819
37. Ghosh A, Larrondo-Petrie MM, Pavlovic M. Revolutionizing vaccine development for COVID-19: a review of AI-based approaches. Information. 2023;14(12):665. DOI: https://doi.org/10.3390/info14120665
38. ElSherif M, Halperin SA. Benefits of combining Molecular Biology and Controlled Human Infection Model methodologies in advancing Vaccine Development. J Mol Biol. 2023;168322. DOI: https://doi.org/10.1016/j.jmb.2023.168322
39. Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020;38(5):523–32. DOI: https://doi.org/10.1038/d41587-020-00005-z
40. Ng’uni T, Chasara C, Ndhlovu ZM. Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol. 2020;11:590780. DOI: https://doi.org/10.3389/fimmu.2020.590780
41. Feldmann-Jensen S, DPPD MPH, O’Sullivan T. Informing Adaptation with Lessons Learned from Key 21st Century Infectious Disease Outbreaks. Current and Emerging Trends in the Management of International Disasters. 2024;
42. Ding C, Liu X, Yang S. The value of infectious disease modeling and trend assessment: a public health perspective. Expert Rev Anti Infect Ther. 2021;19(9):1135–45. DOI: https://doi.org/10.1080/14787210.2021.1882850
43. Sarley D, Hwang A, Hall BF, Ford A, Giersing B, Kaslow DC, et al. Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030. Vaccine. 2022;
44. Aribi M. Development: From Traditional to Modern Approaches. New Topics in Vaccine Development. 2024;3. DOI: https://doi.org/10.5772/intechopen.111005
45. Van Tilbeurgh M, Lemdani K, Beignon AS, Chapon C, Tchitchek N, Cheraitia L, et al. Predictive markers of immunogenicity and efficacy for human vaccines. Vaccines (Basel). 2021;9(6):579. DOI: https://doi.org/10.3390/vaccines9060579
46. Zhang WY, Zheng XL, Coghi PS, Chen JH, Dong BJ, Fan XX. Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines. Front Immunol. 2024;15:1438030. DOI: https://doi.org/10.3389/fimmu.2024.1438030
47. Ananya, Panchariya DC, Karthic A, Singh SP, Mani A, Chawade A, et al. Vaccine design and development: Exploring the interface with computational biology and AI. Int Rev Immunol. 2024;1–20. DOI: https://doi.org/10.1080/08830185.2024.2374546
48. Zhao AP, Li S, Cao Z, Hu PJH, Wang J, Xiang Y, et al. AI for science: predicting infectious diseases. Journal of Safety Science and Resilience. 2024; DOI: https://doi.org/10.1016/j.jnlssr.2024.02.002
49. Vashisht V, Vashisht A, Mondal AK, Farmaha J, Alptekin A, Singh H, et al. Genomics for emerging pathogen identification and monitoring: Prospects and obstacles. BioMedInformatics. 2023;3(4):1145–77. DOI: https://doi.org/10.3390/biomedinformatics3040069
50. Farzan R. Artificial intelligence in Immuno-genetics. Bioinformation. 2024;20(1):29. DOI: https://doi.org/10.6026/973206300200029
51. Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Campbell JP. Introduction to machine learning, neural networks, and deep learning. Transl Vis Sci Technol. 2020;9(2):14.
52. De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol. 2020;11:442. DOI: https://doi.org/10.3389/fimmu.2020.00442
53. Parvizpour S, Pourseif MM, Razmara J, Rafi MA, Omidi Y. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discov Today. 2020;25(6):1034–42. DOI: https://doi.org/10.1016/j.drudis.2020.03.006
54. Khan MA, Amin A, Farid A, Ullah A, Waris A, Shinwari K, et al. Recent advances in genomics-based approaches for the development of intracellular bacterial pathogen vaccines. Pharmaceutics. 2022;15(1):152. DOI: https://doi.org/10.3390/pharmaceutics15010152
55. Bhattacharjee B, Bezbaruah R, Rynjah D, Newar A, Valu D, Ahmed N, et al. Proteogenomics and immunopeptidomics in the development of advanced vaccines. In: Advanced Vaccination Technologies for Infectious and Chronic Diseases. Elsevier; 2024. p. 455–75. DOI: https://doi.org/10.1016/B978-0-443-18564-9.00019-9
56. Angaitkar P, Janghel RR, Sahu TP. DL-TCNN: Deep Learning-based Temporal Convolutional Neural Network for prediction of conformational B-cell epitopes. 3 Biotech. 2023;13(9):297. DOI: https://doi.org/10.1007/s13205-023-03716-7
57. Dhanushkumar T, Santhosh ME, Selvam PK, Rambabu M, Dasegowda KR, Vasudevan K, et al. Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: A comprehensive review of multi-omics and immunomics strategies. Life Sci. 2023;122360. DOI: https://doi.org/10.1016/j.lfs.2023.122360
58. Liu Y, Ouyang X hui, Xiao ZX, Zhang L, Cao Y. A review on the methods of peptide-MHC binding prediction. Curr Bioinform. 2020;15(8):878–88. DOI: https://doi.org/10.2174/1574893615999200429122801
59. Zhang Y, Mastouri M, Zhang Y. Accelerating drug discovery, development, and clinical trials by artificial intelligence. Med. 2024; DOI: https://doi.org/10.1016/j.medj.2024.07.026
60. Bukhari SNH, Jain A, Haq E, Mehbodniya A, Webber J. Machine learning techniques for the prediction of B-cell and T-cell epitopes as potential vaccine targets with a specific focus on SARS-CoV-2 pathogen: A review. Pathogens. 2022;11(2):146. DOI: https://doi.org/10.3390/pathogens11020146
61. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. DOI: https://doi.org/10.1126/sciimmunol.abc8413
62. Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-based vaccines. Vaccines (Basel). 2021;9(4):390. DOI: https://doi.org/10.3390/vaccines9040390
63. Bharadwaj KK, Srivastava A, Panda MK, Singh YD, Maharana R, Mandal K, et al. Computational intelligence in vaccine design against COVID-19. Computational intelligence methods in COVID-19: surveillance, prevention, prediction and diagnosis. 2021;311–29. DOI: https://doi.org/10.1007/978-981-15-8534-0_16
64. Alafif T, Tehame AM, Bajaba S, Barnawi A, Zia S. Machine and deep learning towards COVID-19 diagnosis and treatment: survey, challenges, and future directions. Int J Environ Res Public Health. 2021;18(3):1117. DOI: https://doi.org/10.3390/ijerph18031117
65. Bastola R, Noh G, Keum T, Bashyal S, Seo JE, Choi J, et al. Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res. 2017;40:1238–48. DOI: https://doi.org/10.1007/s12272-017-0969-z
66. Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8(1):283. DOI: https://doi.org/10.1038/s41392-023-01557-7
67. Elhassan Taha MM, Abdelwahab SI, Moni SS, Farasani A, Aljahdali IA, Oraibi B, et al. Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research. Hum Vaccin Immunother. 2024;20(1):2427464. DOI: https://doi.org/10.1080/21645515.2024.2427464
68. Kardani K, Bolhassani A, Namvar A. An overview of in silico vaccine design against different pathogens and cancer. Expert Rev Vaccines. 2020;19(8):699–726. DOI: https://doi.org/10.1080/14760584.2020.1794832
69. Bravi B. Development and use of machine learning algorithms in vaccine target selection. NPJ Vaccines. 2024;9(1):15. DOI: https://doi.org/10.1038/s41541-023-00795-8
70. Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2022;40(4):499–506. DOI: https://doi.org/10.1038/s41587-021-01070-8
71. Moni SS, Abdelwahab SI, Jabeen A, Elmobark ME, Aqaili D, Gohal G, et al. Advancements in vaccine adjuvants: The journey from alum to nano formulations. Vaccines (Basel). 2023;11(11):1704. DOI: https://doi.org/10.3390/vaccines11111704
72. Pulendran B, S. Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75. DOI: https://doi.org/10.1038/s41573-021-00163-y
73. Xu J, Liu W, Fan F, Zhang B, Sun C, Hu Y. Advances in nano-immunotherapy for hematological malignancies. Exp Hematol Oncol. 2024;13(1):57. DOI: https://doi.org/10.1186/s40164-024-00525-3
74. Pasupuleti D, Bagwe P, Ferguson A, Uddin MN, D’Souza MJ, Zughaier SM. Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay. Vaccines (Basel). 2024;12(9):1049. DOI: https://doi.org/10.3390/vaccines12091049
75. Russo G, Reche P, Pennisi M, Pappalardo F. The combination of artificial intelligence and systems biology for intelligent vaccine design. Expert Opin Drug Discov. 2020;15(11):1267–81. DOI: https://doi.org/10.1080/17460441.2020.1791076
76. Shin B, An G, Cockrell RC. Examining B-cell dynamics and responsiveness in different inflammatory milieus using an agent-based model. PLoS Comput Biol. 2024;20(1):e1011776. DOI: https://doi.org/10.1371/journal.pcbi.1011776
77. Jamali Y. Modeling the Immune System Through Agent-based Modeling: A Mini-review. Immunoregulation. 2024;6(1):3–12. DOI: https://doi.org/10.32598/Immunoregulation.6.1.7
78. Handel A, La Gruta NL, Thomas PG. Simulation modelling for immunologists. Nat Rev Immunol. 2020;20(3):186–95. DOI: https://doi.org/10.1038/s41577-019-0235-3
79. Hayawi K, Shahriar S, Alashwal H, Serhani MA. Generative AI and Large Language Models: A New Frontier in Reverse Vaccinology. Inform Med Unlocked. 2024;101533. DOI: https://doi.org/10.1016/j.imu.2024.101533
80. Chavda VP, Ghali ENHK, Balar PC, Chauhan SC, Tiwari N, Shukla S, et al. Protein subunit vaccines: Promising frontiers against COVID-19. Journal of Controlled Release. 2024;366:761–82. DOI: https://doi.org/10.1016/j.jconrel.2024.01.017
81. Bali A, Bali N. Role of artificial intelligence in fast-track drug discovery and vaccine development for COVID-19. In: Novel AI and Data Science Advancements for Sustainability in the Era of COVID-19. Elsevier; 2022. p. 201–29. DOI: https://doi.org/10.1016/B978-0-323-90054-6.00006-4
82. Gao W, Liu J, Shtylla B, Venkatakrishnan K, Yin D, Shah M, et al. Realizing the promise of project optimus: challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics Syst Pharmacol. 2024;13(5):691–709. DOI: https://doi.org/10.1002/psp4.13079
83. Poweleit EA, Vinks AA, Mizuno T. Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. Ther Drug Monit. 2023;45(2):143–50. DOI: https://doi.org/10.1097/FTD.0000000000001078
84. Liu M, Li Q, Lin J, Lin Y, Hoffman E. Innovative trial designs and analyses for vaccine clinical development. Contemp Clin Trials. 2021;100:106225. DOI: https://doi.org/10.1016/j.cct.2020.106225
85. Chen X, He R, Chen X, Jiang L, Wang F. Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges. Front Pharmacol. 2023;14:1261312. DOI: https://doi.org/10.3389/fphar.2023.1261312
86. Guarra F, Colombo G. Computational Methods in Immunology and Vaccinology: Design and Development of Antibodies and Immunogens. J Chem Theory Comput. 2023;19(16):5315–33. DOI: https://doi.org/10.1021/acs.jctc.3c00513
87. Ortiz JPH, Osorio JE. One Health and Engineering: using engineering to further pave the roadmap towards global health security, pandemic preparedness, and personalized medicine. DYNA: revista de la Facultad de Minas Universidad Nacional de Colombia Sede Medellín. 2023;90(230):22–8. DOI: https://doi.org/10.15446/dyna.v90n230.111828
88. Danchin A. Artificial intelligence‐based prediction of pathogen emergence and evolution in the world of synthetic biology. Microb Biotechnol. 2024;17(10):e70014. DOI: https://doi.org/10.1111/1751-7915.70014
89. Domingo E, García-Crespo C, Lobo-Vega R, Perales C. Mutation rates, mutation frequencies, and proofreading-repair activities in RNA virus genetics. Viruses. 2021;13(9):1882. DOI: https://doi.org/10.3390/v13091882
90. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021;22(3):137–53. DOI: https://doi.org/10.1038/s41576-020-00297-6
91. Al-Amran FG, Hezam AM, Rawaf S, Yousif MG. Genomic Analysis and Artificial Intelligence: Predicting Viral Mutations and Future Pandemics. arXiv preprint arXiv:230915936. 2023;
92. Nawaz MS, Fournier-Viger P, Shojaee A, Fujita H. Using artificial intelligence techniques for COVID-19 genome analysis. Applied Intelligence. 2021;51:3086–103. DOI: https://doi.org/10.1007/s10489-021-02193-w
93. Mohanty E, Mohanty A. Role of artificial intelligence in peptide vaccine design against RNA viruses. Inform Med Unlocked. 2021;26:100768. DOI: https://doi.org/10.1016/j.imu.2021.100768
94. Bernasconi A. The opportunity of data-driven services for viral genomic surveillance. In: 2023 IEEE International Conference on Service-Oriented System Engineering (SOSE). IEEE; 2023. p. 172–81. DOI: https://doi.org/10.1109/SOSE58276.2023.00028
95. Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020;19(4):239–52. DOI: https://doi.org/10.1038/s41573-019-0056-x
96. Dănăilă VR, Avram S, Buiu C. The applications of machine learning in HIV neutralizing antibodies research—A systematic review. Artif Intell Med. 2022;134:102429. DOI: https://doi.org/10.1016/j.artmed.2022.102429
97. Hederman AP, Ackerman ME. Leveraging deep learning to improve vaccine design. Trends Immunol. 2023;44(5):333–44. DOI: https://doi.org/10.1016/j.it.2023.03.002
98. Irvine EB, Reddy ST. Advancing antibody engineering through synthetic evolution and machine learning. The Journal of Immunology. 2024;212(2):235–43. DOI: https://doi.org/10.4049/jimmunol.2300492
99. Elste J, Saini A, Mejia-Alvarez R, Mejía A, Millán-Pacheco C, Swanson-Mungerson M, et al. Significance of Artificial Intelligence in the Study of Virus–Host Cell Interactions. Biomolecules. 2024;14(8):911. DOI: https://doi.org/10.3390/biom14080911
100. Ghosh A, Pavlovic M, Larrondo-Petrie MM. Rational Vaccine Design for SARS-CoV-2 Virus—A Systematic Review. 2023; DOI: https://doi.org/10.20944/preprints202311.1607.v1
101. Taft JM, Weber CR, Gao B, Ehling RA, Han J, Frei L, et al. Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. Cell. 2022;185(21):4008–22. DOI: https://doi.org/10.1016/j.cell.2022.08.024
102. Scarpa F, Casu M. Genomics and Bioinformatics in One Health: Transdisciplinary Approaches for Health Promotion and Disease Prevention. Int J Environ Res Public Health. 2024;21(10):1337. DOI: https://doi.org/10.3390/ijerph21101337
103. Ling-Hu T, Rios-Guzman E, Lorenzo-Redondo R, Ozer EA, Hultquist JF. Challenges and opportunities for global genomic surveillance strategies in the COVID-19 era. Viruses. 2022;14(11):2532. DOI: https://doi.org/10.3390/v14112532
104. Padhi A, Agarwal A, Saxena SK, Katoch CDS. Transforming clinical virology with AI, machine learning and deep learning: a comprehensive review and outlook. Virusdisease. 2023;34(3):345–55. DOI: https://doi.org/10.1007/s13337-023-00841-y
105. Bedi R, Bayless NL, Glanville J. Challenges and progress in designing broad-spectrum vaccines against rapidly mutating viruses. Annu Rev Biomed Data Sci. 2023;6(1):419–41. DOI: https://doi.org/10.1146/annurev-biodatasci-020722-041304
106. Aminu RF, Emurotu MO, Mofolorunsho KC. Applications of Molecular Phylogeny in Disease Diagnosis. Int J Res Virol. 2024;1(1):1–8. DOI: https://doi.org/10.33425/3065-565X.1004
107. Ochsenreiter RW. Algorithmic Approaches on Structural RNA Evolution in Viruses. 2023;
108. Kushwaha SK, Kesarwani V, Choudhury S, Gandhi S, Sharma S. SARS-CoV-2 transcriptome analysis and molecular cataloguing of immunodominant epitopes for multi-epitope based vaccine design. Genomics. 2020;112(6):5044–54. DOI: https://doi.org/10.1016/j.ygeno.2020.09.019
109. Rastogi A, Gautam S, Kumar M. Bioinformatic elucidation of conserved epitopes to design a potential vaccine candidate against existing and emerging SARS-CoV-2 variants of concern. Heliyon. 2024;10(15). DOI: https://doi.org/10.1016/j.heliyon.2024.e35129
110. Giurgea LT, Morens DM, Taubenberger JK, Memoli MJ. Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine. Vaccines (Basel). 2020;8(3):409. DOI: https://doi.org/10.3390/vaccines8030409
111. Biswas A, Chakrabarti AK, Dutta S. Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines: flu vaccine efficacy encounters significant hurdles from pre-existing immunity of the host suggesting assessment of host immunity before vaccination. Int Rev Immunol. 2020;39(1):21–36. DOI: https://doi.org/10.1080/08830185.2019.1685990
112. Mahomed S. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives. Clin Microbiol Rev. 2024;e00152-22. DOI: https://doi.org/10.1128/cmr.00152-22
113. Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077. DOI: https://doi.org/10.3389/fimmu.2020.583077
114. Prabhod KJ. The Role of Machine Learning in Genomic Medicine: Advancements in Disease Prediction and Treatment. Journal of Deep Learning in Genomic Data Analysis. 2022;2(1):1–52.
115. Montesinos-López OA, Montesinos-López A, Pérez-Rodríguez P, Barrón-López JA, Martini JWR, Fajardo-Flores SB, et al. A review of deep learning applications for genomic selection. BMC Genomics. 2021;22:1–23. DOI: https://doi.org/10.1186/s12864-020-07319-x
116. Loewa A, Feng JJ, Hedtrich S. Human disease models in drug development. Nature reviews bioengineering. 2023;1(8):545–59. DOI: https://doi.org/10.1038/s44222-023-00063-3
117. Baquero F, Martinez JL, F. Lanza V, Rodríguez-Beltrán J, Galán JC, San Millán A, et al. Evolutionary pathways and trajectories in antibiotic resistance. Clin Microbiol Rev. 2021;34(4):e00050-19. DOI: https://doi.org/10.1128/CMR.00050-19
118. Williams D, Hornung H, Nadimpalli A, Peery A. Deep learning and its application for healthcare delivery in low and middle income countries. Front Artif Intell. 2021;4:553987. DOI: https://doi.org/10.3389/frai.2021.553987
119. Naseem M, Akhund R, Arshad H, Ibrahim MT. Exploring the potential of artificial intelligence and machine learning to combat COVID-19 and existing opportunities for LMIC: a scoping review. J Prim Care Community Health. 2020;11:2150132720963634. DOI: https://doi.org/10.1177/2150132720963634
120. Ebulue CC, Ekkeh OV, Ebulue OR, Ekesiobi CS. Leveraging machine learning for vaccine distribution in resource-limited settings: A synthesis of approaches. International Medical Science Research Journal. 2024;4(5):544–57. DOI: https://doi.org/10.51594/imsrj.v4i5.1120
121. Srivastava V, Kumar R, Wani MY, Robinson K, Ahmad A. Role of artificial intelligence in early diagnosis and treatment of infectious diseases. Infect Dis. 2024;1–26. DOI: https://doi.org/10.1080/23744235.2024.2425712
122. Abbasi N, Nizamullah FNU, Zeb S. AI IN HEALTHCARE: USING CUTTING-EDGE TECHNOLOGIES TO REVOLUTIONIZE VACCINE DEVELOPMENT AND DISTRIBUTION. JURIHUM: Jurnal Inovasi dan Humaniora. 2023;1(1):17–29.
123. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, et al. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics. Curr Pharm Biotechnol. 2024;25(16):2060–77. DOI: https://doi.org/10.2174/0113892010275850240102105033
124. Khuat TT, Bassett R, Otte E, Grevis-James A, Gabrys B. Applications of machine learning in biopharmaceutical process development and manufacturing: Current trends, challenges, and opportunities. arXiv preprint arXiv:231009991. 2023; DOI: https://doi.org/10.1016/j.compchemeng.2024.108585
125. Sharma A, Virmani T, Pathak V, Sharma A, Pathak K, Kumar G, et al. Artificial intelligence‐based data‐driven strategy to accelerate research, development, and clinical trials of COVID vaccine. Biomed Res Int. 2022;2022(1):7205241. DOI: https://doi.org/10.1155/2022/7205241
126. Rappuoli R, Alter G, Pulendran B. Transforming vaccinology. Cell. 2024;187(19):5171–94. DOI: https://doi.org/10.1016/j.cell.2024.07.021
127. Pertseva M, Gao B, Neumeier D, Yermanos A, Reddy ST. Applications of machine and deep learning in adaptive immunity. Annu Rev Chem Biomol Eng. 2021;12(1):39–62. DOI: https://doi.org/10.1146/annurev-chembioeng-101420-125021
128. Bansal H, Aggarwal N. 19 Artificial Techniques Intelligenceto Design Epitope-Mapped. Handbook of AI-Based Models in Healthcare and Medicine: Approaches, Theories, and Applications. 2024;378.
129. Bansal H, Aggarwal N. Artificial Intelligence Techniques to Design Epitope-Mapped Vaccines and Diagnostics for Emerging Pathogens. In: Handbook of AI-Based Models in Healthcare and Medicine. CRC Press; p. 378–96. DOI: https://doi.org/10.1201/9781003363361-19
130. Malone B, Simovski B, Moliné C, Cheng J, Gheorghe M, Fontenelle H, et al. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs. Sci Rep. 2020;10(1):22375. DOI: https://doi.org/10.1038/s41598-020-78758-5
131. Slieker RC, Warmerdam DO, Vermeer MH, van Doorn R, Heemskerk MHM, Scheeren FA. Reassessing human MHC-I genetic diversity in T cell studies. Sci Rep. 2024;14(1):7966. DOI: https://doi.org/10.1038/s41598-024-58777-2
132. Deng Z. Pandemic-Resilient Investment: Sustainable Knowledge Infrastructure for Medical AI. Journal of the Knowledge Economy. 2024;1–24. DOI: https://doi.org/10.1007/s13132-024-01874-4
133. Pillai AS. Artificial Intelligence in Healthcare Systems of Low-and Middle-Income Countries: Requirements, Gaps, Challenges, and Potential Strategies. International Journal of Applied Health Care Analytics. 2023;8(3):19–33.
134. Gleeson D, Townsend B, Tenni BF, Phillips T. Global inequities in access to COVID-19 health products and technologies: a political economy analysis. Health Place. 2023;83:103051. DOI: https://doi.org/10.1016/j.healthplace.2023.103051
135. Ritoré Á, Jiménez CM, González JL, Rejón-Parrilla JC, Hervás P, Toro E, et al. The role of Open Access Data in democratizing healthcare AI: A pathway to research enhancement, patient well-being and treatment equity in Andalusia, Spain. PLOS Digital Health. 2024;3(9):e0000599. DOI: https://doi.org/10.1371/journal.pdig.0000599
136. Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: A call for open science. Patterns. 2021;2(10). DOI: https://doi.org/10.1016/j.patter.2021.100347
137. Schleiss MR, Crooks CM, Karthigeyan KP, Kruc RM, Otero CE, Wang HY, et al. Proceedings of the Conference “CMV Vaccine Development—How Close Are We?”(27–28 September 2023). MDPI; 2024. DOI: https://doi.org/10.3390/vaccines12111231
138. Jean-Jacques M, Bauchner H. Vaccine distribution—equity left behind? JAMA. 2021;325(9):829–30. DOI: https://doi.org/10.1001/jama.2021.1205
139. Topol E. Deep medicine: how artificial intelligence can make healthcare human again. Hachette UK; 2019.
140. Balagurunathan Y, Sethuraman RR. An Analysis of Ethics-Based Foundation and Regulatory Issues for Genomic Data Privacy. Journal of The Institution of Engineers (India): Series B. 2024;1–11. DOI: https://doi.org/10.1007/s40031-024-01058-3
141. Adekugbe AP, Ibeh CV. Navigating ethical challenges in data management for US program development: best practices and recommendations. International Journal of Management & Entrepreneurship Research. 2024;6(4):1023–33. DOI: https://doi.org/10.51594/ijmer.v6i4.982
142. Kaushik R, Kant R, Christodoulides M. Artificial intelligence in accelerating vaccine development-current and future perspectives. Frontiers in Bacteriology. 2023;2:1258159. DOI: https://doi.org/10.3389/fbrio.2023.1258159
143. Oyeniran CO, Adewusi AO, Adeleke AG, Akwawa LA, Azubuko CF. Ethical AI: Addressing bias in machine learning models and software applications. Computer Science & IT Research Journal. 2022;3(3):115–26. DOI: https://doi.org/10.51594/csitrj.v3i3.1559
144. Agampodi S, Mogeni OD, Chandler R, Pansuriya M, Kim JH, Excler JL. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution. Expert Rev Vaccines. 2024;23(1):761–72. DOI: https://doi.org/10.1080/14760584.2024.2395546
145. Chen J, Li K, Zhang Z, Li K, Yu PS. A survey on applications of artificial intelligence in fighting against COVID-19. ACM Computing Surveys (CSUR). 2021;54(8):1–32. DOI: https://doi.org/10.1145/3465398
146. Casalino L, Dommer AC, Gaieb Z, Barros EP, Sztain T, Ahn SH, et al. AI-driven multiscale simulations illuminate mechanisms of SARS-CoV-2 spike dynamics. Int J High Perform Comput Appl. 2021;35(5):432–51. DOI: https://doi.org/10.1177/10943420211006452
147. Arora G, Joshi J, Mandal RS, Shrivastava N, Virmani R, Sethi T. Artificial intelligence in surveillance, diagnosis, drug discovery and vaccine development against COVID-19. Pathogens. 2021;10(8):1048. DOI: https://doi.org/10.3390/pathogens10081048
148. Nejat R, Torshizi MF, Najafi DJ. S protein, ACE2 and host cell proteases in SARS-CoV-2 cell entry and infectivity; is soluble ACE2 a two blade sword? A narrative review. Vaccines (Basel). 2023;11(2):204. DOI: https://doi.org/10.3390/vaccines11020204
149. Sanyal D, Banerjee S, Bej A, Chowdhury VR, Uversky VN, Chowdhury S, et al. An integrated understanding of the evolutionary and structural features of the SARS-CoV-2 spike receptor binding domain (RBD). Int J Biol Macromol. 2022;217:492–505. DOI: https://doi.org/10.1016/j.ijbiomac.2022.07.022
150. Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700. DOI: https://doi.org/10.3390/ijms24032700
151. Macarayan E, Papanicolas I, Jha A. The quality of malaria care in 25 low-income and middle-income countries. BMJ Glob Health. 2020;5(2):e002023. DOI: https://doi.org/10.1136/bmjgh-2019-002023
152. Rajneesh, Tiwari R, Singh VK, Kumar A, Gupta RP, Singh AK, et al. Advancements and challenges in developing malaria vaccines: Targeting multiple stages of the parasite life cycle. ACS Infect Dis. 2023;9(10):1795–814. DOI: https://doi.org/10.1021/acsinfecdis.3c00332
153. Wong F, de la Fuente-Nunez C, Collins JJ. Leveraging artificial intelligence in the fight against infectious diseases. Science (1979). 2023;381(6654):164–70. DOI: https://doi.org/10.1126/science.adh1114
154. Musundi SD, Gitaka J, Kanoi BN. Identification of conserved cross-species B-cell linear epitopes in human malaria: A subtractive proteomics and immuno-informatics approach targeting merozoite stage proteins. Front Immunol. 2024;15:1352618. DOI: https://doi.org/10.3389/fimmu.2024.1352618
155. Taddese S. Status in Malaria Vaccine Development: Basic aspects of Vaccine, Mechanism of actions, Vaccine pipelines, Stage oriented immune response ‘Challenges and Opportunities.’ Microbial journal. 2023;3(1). DOI: https://doi.org/10.59411/990get50
156. Malik S, Waheed Y. Recent advances on vaccines against malaria: A review. Asian Pac J Trop Med. 2024;17(4):143–59. DOI: https://doi.org/10.4103/apjtm.apjtm_678_23
157. Duffy PE. Current approaches to malaria vaccines. Curr Opin Microbiol. 2022;70:102227. DOI: https://doi.org/10.1016/j.mib.2022.102227
158. Ali ST, Cowling BJ. Influenza virus: tracking, predicting, and forecasting. Annu Rev Public Health. 2021;42(1):43–57. DOI: https://doi.org/10.1146/annurev-publhealth-010720-021049
159. Luczo JM, Spackman E. Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift. FEMS Microbiol Rev. 2024;48(3). DOI: https://doi.org/10.1093/femsre/fuae014
160. Russell CA, Fouchier RAM, Ghaswalla P, Park Y, Vicic N, Ananworanich J, et al. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum Vaccin Immunother. 2024;20(1):2336357. DOI: https://doi.org/10.1080/21645515.2024.2336357
161. Rcheulishvili N, Mao J, Papukashvili D, Liu C, Wang Z, Zhao J, et al. Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness. Int J Biol Macromol. 2023;226:885–99. DOI: https://doi.org/10.1016/j.ijbiomac.2022.12.066
162. Sparrow E, Wood JG, Chadwick C, Newall AT, Torvaldsen S, Moen A, et al. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine. 2021;39(3):512–20. DOI: https://doi.org/10.1016/j.vaccine.2020.12.018
163. Montero DA, Vidal RM, Velasco J, Carreño LJ, Torres JP, Benachi O MA, et al. Two centuries of vaccination: historical and conceptual approach and future perspectives. Front Public Health. 2024;11:1326154. DOI: https://doi.org/10.3389/fpubh.2023.1326154
164. Lu G, Shan S, Zainab B, Ayaz Z, He J, Xie Z, et al. Novel vaccine design based on genomics data analysis: A review. Scand J Immunol. 2021;93(3):e12986. DOI: https://doi.org/10.1111/sji.12986
165. Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Influenza neuraminidase characteristics and potential as a vaccine target. Front Immunol. 2021;12:786617. DOI: https://doi.org/10.3389/fimmu.2021.786617
166. Mandala WL, Harawa V, Dzinjalamala F, Tembo D. The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development. Mol Biochem Parasitol. 2021;246:111425. DOI: https://doi.org/10.1016/j.molbiopara.2021.111425
167. Matsuzaka Y, Yashiro R. Understanding and Therapeutic Application of Immune Response in Major Histocompatibility Complex (MHC) Diversity Using Multimodal Artificial Intelligence. BioMedInformatics. 2024;4(3):1835–64. DOI: https://doi.org/10.3390/biomedinformatics4030101
168. Munagandla VB, Dandyala SSV, Vadde BC. AI-Powered Cloud-Based Epidemic Surveillance System: A Framework for Early Detection. Revista de Inteligencia Artificial en Medicina. 2024;15(1):673–90.
169. Bag AK, Sengupta D. Computational frameworks for zoonotic disease control in Society 5.0: opportunities, challenges and future research directions. AI Soc. 2024;1–30. DOI: https://doi.org/10.1007/s00146-024-01992-2
Published
Issue
Section
License
Copyright (c) 2024 Diana Catalina Velastegui-Hernandez, Luis Felipe Contreras-Vásquez, Gabriela Sandoval, Andrea Alexandra Tufiño-Aguilar, Andrea Carolina Cevallos-Teneda, Estefania Araceli Reyes-Rosero, Verónica Gabriela Salinas-Velastegui, Rita Elizabeth Velastegui-Hernández, Fabricio Alejandro Vasquez de la Bandera, Luis Fabián Salazar-Garcés (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
